Hallucinogenic drugs are now seen as a potential cure for depression, alcoholism and a means to get people off opioids. Photo Media/ClassicStock/Getty Images
We all know the lore of LSD microdosing in Silicon Valley. It’s been hailed as a job-enhancer in the tech industry. A very small dosage, around 10-15 micrograms, has been ...
A psychedelic drug with the potential to cure addiction is set to undergo human trials in America next year.
Psychedelics have long been known to inhibit cravings and help fight addiction, but a litany of ethical, health and legal issues have made them unsuitable as a treatment.
18-MC is made from an intense African shrub called ibogaine which can induce intense trips – including hallucinations and visions – lasting several days.
But the version ...
SAN DIEGO — People across the country are crossing the border to Mexico, hoping an alternative form of therapy will cure their addiction to opioids.
One former addict shared his story with Scripps station KGTV in San Diego. He asked that he only be referred to as Bob.
“I had been to traditional rehabs throughout my life, mostly against my will,” said Bob.
He said he got hooked on painkillers after multiple injuries due to ...
There is a catch, however: ibogaine, the key ingredient in the non-hallucinogenic compound 18-MC, is classified as a Schedule 1 drug in the US, …
Psychedelic medicine is hot right now—or regulatory agencies seem to be warming up to the idea, at least. Over the last few years, the FDA has begun to approve (and even fast-track) clinical trials examining the impact of substances like ketamine, psilocybin, and MDMA on mental health issues like post-traumatic stress disorder and major depressive disorder. In addition to contributing to the growing ...